Literature DB >> 29485794

Chronic Obstructive Pulmonary Disease and Heart Failure: Closer than Close.

Jelena Ostojić1, Hrvoje Pintarić2.   

Abstract

Chronic obstructive pulmonary disease (COPD) and heart failure (HF) both are global epidemics with substantial burden on morbidity and mortality. They present major challenges to healthcare providers and often coexsist. Multiple interactions exist between these conditions. COPD is often responsible for delayed diagnosis of HF and vice versa, since both conditions have similar symptoms such as dyspnea and poor exercise tolerance based on the skeletal myopathic response rather than the primary organ failure. Patients with COPD also have an increased risk of developing HF and higher hospitalization and death rates compared with HF patients without COPD. Echocardiography and pulmonary function tests along with natriuretic peptides should be performed and carefully interpreted. Diagnostic assessment of both conditions present in the same patient is often difficult, but therapeutic approach is also often non-adherent to current guidelines. For example, patients with coexisting COPD and HF receive beta-blockers at disappointingly low rates below 20%. Closer collaboration between cardiologists and pulmonologists is required for better identification and management of concurrent COPD and HF.

Entities:  

Keywords:  Echocardiography; Heart failure – diagnosis; Pulmonary disease, chronic obstructive – diagnosis; Pulmonary disease, chronic obstructive – therapy; Respiratory function tests

Mesh:

Year:  2017        PMID: 29485794     DOI: 10.20471/acc.2017.56.02.10

Source DB:  PubMed          Journal:  Acta Clin Croat        ISSN: 0353-9466            Impact factor:   0.780


  3 in total

1.  Association between tumor necrosis factor-α and chronic obstructive pulmonary disease: a systematic review and meta-analysis.

Authors:  Yang Yao; Jing Zhou; Xin Diao; Shengyu Wang
Journal:  Ther Adv Respir Dis       Date:  2019 Jan-Dec       Impact factor: 4.031

2.  Cognitive impairment, frailty and rehabilitation outcome in older cardiorespiratory patients. DEC_FRAinRIAB: Study protocol.

Authors:  Martina Vigorè; Nicolò Granata; Simona Sarzi Braga; Giancarlo Piaggi; Silvia Audifreddi; Marina Ferrari; Maria Teresa La Rovere; Antonia Pierobon
Journal:  PLoS One       Date:  2022-08-04       Impact factor: 3.752

3.  Selective activation of pro-anti-IL-1β antibody enhances specificity for autoinflammatory disorder therapy.

Authors:  Wen-Wei Lin; Yun-Chi Lu; Bo-Cheng Huang; Chih-Hung Chuang; Yi-An Cheng; I-Ju Chen; Hui-Ju Liu; Kai-Wen Ho; Tzu-Yi Liao; En-Shuo Liu; Ting-Yi Wu; Long-Sen Chang; Shih-Ting Hong; Tian-Lu Cheng
Journal:  Sci Rep       Date:  2021-07-21       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.